Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

The association between maternal occupation and down syndrome: A report from the national Down syndrome project.

Keen C, Hunter JE, Allen EG, Rocheleau C, Waters M, Sherman SL.

Int J Hyg Environ Health. 2019 Sep 10. pii: S1438-4639(19)30435-3. doi: 10.1016/j.ijheh.2019.09.001. [Epub ahead of print]

PMID:
31519426
2.

Clinical Molecular Marker Testing Data Capture to Promote Precision Medicine Research Within the Cancer Research Network.

Burnett-Hartman AN, Udaltsova N, Kushi LH, Neslund-Dudas C, Rahm AK, Pawloski PA, Corley DA, Knerr S, Feigelson HS, Hunter JE, Tabano DC, Epstein MM, Honda SA, Ter-Minassian M, Lynch JA, Lu CY.

JCO Clin Cancer Inform. 2019 Sep;3:1-10. doi: 10.1200/CCI.19.00026.

3.

The Skin You Are In: Design-of-Experiments Optimization of Lipid Nanoparticle Self-Amplifying RNA Formulations in Human Skin Explants.

Blakney AK, McKay PF, Ibarzo Yus B, Hunter JE, Dex EA, Shattock RJ.

ACS Nano. 2019 May 28;13(5):5920-5930. doi: 10.1021/acsnano.9b01774. Epub 2019 May 3.

4.

Expert and lay perspectives on burden, risk, tolerability, and acceptability of clinical interventions for genetic disorders.

Paquin RS, Mittendorf KF, Lewis MA, Hunter JE, Lee K, Berg JS, Williams MS, Goddard KAB.

Genet Med. 2019 Apr 26. doi: 10.1038/s41436-019-0524-z. [Epub ahead of print]

PMID:
31028355
5.

The Healthcare Systems Research Network (HCSRN) as an Environment for Dissemination and Implementation Research: A Case Study of Developing a Multi-Site Research Study in Precision Medicine.

Rahm AK, Ladd I, Burnett-Hartman AN, Epstein MM, Lowery JT, Lu CY, Pawloski PA, Sharaf RN, Liang SY, Hunter JE.

EGEMS (Wash DC). 2019 Apr 12;7(1):16. doi: 10.5334/egems.283.

6.

Feasibility of an app-based mindfulness intervention among women with an FMR1 premutation experiencing maternal stress.

Hunter JE, Jenkins CL, Grim V, Leung S, Charen KH, Hamilton DR, Allen EG, Sherman SL.

Res Dev Disabil. 2019 Jun;89:76-82. doi: 10.1016/j.ridd.2019.03.008. Epub 2019 Apr 5.

PMID:
30959430
7.

In Situ Hybridization for Detection of AAV-Mediated Gene Expression.

Hunter JE, Gurda BL, Yoon SY, Castle MJ, Wolfe JH.

Methods Mol Biol. 2019;1950:107-122. doi: 10.1007/978-1-4939-9139-6_6.

PMID:
30783970
8.

Implementation of a Systematic Tumor Screening Program for Lynch Syndrome in an Integrated Health Care Setting.

Clarke EV, Muessig KR, Zepp J, Hunter JE, Syngal S, Acheson LS, Wiesner GL, Peterson SK, Bergen KM, Shuster E, Davis JV, Schneider JL, Kauffman TL, Gilmore MJ, Reiss JA, Rope AF, Cook JE, Goddard KAB.

Fam Cancer. 2019 Jul;18(3):317-325. doi: 10.1007/s10689-019-00123-x.

PMID:
30729418
9.

Implementing universal Lynch syndrome screening (IMPULSS): protocol for a multi-site study to identify strategies to implement, adapt, and sustain genomic medicine programs in different organizational contexts.

Rahm AK, Cragun D, Hunter JE, Epstein MM, Lowery J, Lu CY, Pawloski PA, Sharaf RN, Liang SY, Burnett-Hartman AN, Gudgeon JM, Hao J, Snyder S, Gogoi R, Ladd I, Williams MS.

BMC Health Serv Res. 2018 Oct 30;18(1):824. doi: 10.1186/s12913-018-3636-2.

10.

Evidence-based assessments of clinical actionability in the context of secondary findings: Updates from ClinGen's Actionability Working Group.

Webber EM, Hunter JE, Biesecker LG, Buchanan AH, Clarke EV, Currey E, Dagan-Rosenfeld O, Lee K, Lindor NM, Martin CL, Milosavljevic A, Mittendorf KF, Muessig KR, O'Daniel JM, Patel RY, Ramos EM, Rego S, Slavotinek AM, Sobriera NLM, Weaver MA, Williams MS, Evans JP, Goddard KAB; ClinGen Resource.

Hum Mutat. 2018 Nov;39(11):1677-1685. doi: 10.1002/humu.23631.

PMID:
30311382
11.

Crop Protection Discovery: Is Being the First Best?

Sparks TC, Hunter JE, Lorsbach BA, Hanger G, Gast RE, Kemmitt G, Bryant RJ.

J Agric Food Chem. 2018 Oct 10;66(40):10337-10346. doi: 10.1021/acs.jafc.8b03484. Epub 2018 Sep 26. Review.

PMID:
30205003
12.

Factors that predict deep inferior epigastric perforator flap donor site hernia and bulge.

Butler DP, Plonczak AM, Reissis D, Henry FP, Hunter JE, Wood SH, Jallali N.

J Plast Surg Hand Surg. 2018 Dec;52(6):338-342. doi: 10.1080/2000656X.2018.1498790. Epub 2018 Sep 4.

PMID:
30178700
13.

Patient and provider perspectives on adherence to and care coordination of lynch syndrome surveillance recommendations: findings from qualitative interviews.

Schneider JL, Goddard KAB, Muessig KR, Davis JV, Rope AF, Hunter JE, Peterson SK, Acheson LS, Syngal S, Wiesner GL, Reiss JA.

Hered Cancer Clin Pract. 2018 May 10;16:11. doi: 10.1186/s13053-018-0090-4. eCollection 2018.

14.

Coccolithovirus facilitation of carbon export in the North Atlantic.

Laber CP, Hunter JE, Carvalho F, Collins JR, Hunter EJ, Schieler BM, Boss E, More K, Frada M, Thamatrakoln K, Brown CM, Haramaty L, Ossolinski J, Fredricks H, Nissimov JI, Vandzura R, Sheyn U, Lehahn Y, Chant RJ, Martins AM, Coolen MJL, Vardi A, DiTullio GR, Van Mooy BAS, Bidle KD.

Nat Microbiol. 2018 May;3(5):537-547. doi: 10.1038/s41564-018-0128-4. Epub 2018 Mar 12.

PMID:
29531367
15.

Lipidomics of Thalassiosira pseudonana under Phosphorus Stress Reveal Underlying Phospholipid Substitution Dynamics and Novel Diglycosylceramide Substitutes.

Hunter JE, Brandsma J, Dymond MK, Koster G, Moore CM, Postle AD, Mills RA, Attard GS.

Appl Environ Microbiol. 2018 Mar 1;84(6). pii: e02034-17. doi: 10.1128/AEM.02034-17. Print 2018 Mar 15.

16.

Thromboprophylaxis in autologous breast reconstruction.

Vamadeva SV, Henry FP, Hunter JE, Wood SH, Jallali N.

J Plast Reconstr Aesthet Surg. 2018 Mar;71(3):434-435. doi: 10.1016/j.bjps.2017.09.013. Epub 2017 Oct 10. No abstract available.

PMID:
29102286
17.

Empirical research evaluating the effects of non-traditional approaches to enhancing sleep in typical and clinical children and young people.

France KG, McLay LK, Hunter JE, France MLS.

Sleep Med Rev. 2018 Jun;39:69-81. doi: 10.1016/j.smrv.2017.07.004. Epub 2017 Jul 29. Review.

PMID:
28918314
18.

Comment on myocutaneous gracilis free flaps for unilateral breast reconstruction.

Vamadeva SV, Hunter JE.

Microsurgery. 2017 Oct;37(7):843. doi: 10.1002/micr.30212. Epub 2017 Aug 14. No abstract available.

PMID:
28805941
19.

Universal screening for Lynch syndrome among patients with colorectal cancer: patient perspectives on screening and sharing results with at-risk relatives.

Hunter JE, Arnold KA, Cook JE, Zepp J, Gilmore MJ, Rope AF, Davis JV, Bergen KM, Esterberg E, Muessig KR, Peterson SK, Syngal S, Acheson L, Wiesner G, Reiss J, Goddard KAB.

Fam Cancer. 2017 Jul;16(3):377-387. doi: 10.1007/s10689-017-9972-2.

20.

Lead generation in crop protection research: a portfolio approach to agrochemical discovery.

Loso MR, Garizi N, Hegde VB, Hunter JE, Sparks TC.

Pest Manag Sci. 2017 Apr;73(4):678-685. doi: 10.1002/ps.4336. Epub 2016 Aug 12.

PMID:
27301075
21.

A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation.

Hunter JE, Irving SA, Biesecker LG, Buchanan A, Jensen B, Lee K, Martin CL, Milko L, Muessig K, Niehaus AD, O'Daniel J, Piper MA, Ramos EM, Schully SD, Scott AF, Slavotinek A, Sobreira N, Strande N, Weaver M, Webber EM, Williams MS, Berg JS, Evans JP, Goddard KA.

Genet Med. 2016 Dec;18(12):1258-1268. doi: 10.1038/gim.2016.40. Epub 2016 Apr 28.

22.

Albumin resuscitation in burns: a hybrid regime to mitigate fluid creep.

Hunter JE, Drew PJ, Potokar TS, Dickson W, Hemington-Gorse SJ.

Scars Burn Heal. 2016 Apr 22;2:2059513116642083. doi: 10.1177/2059513116642083. eCollection 2016 Jan-Dec.

23.

Genetic effects on sleep/wake variation of seizures.

Winawer MR, Shih J, Beck ES, Hunter JE, Epstein MP; EPGP Investigators.

Epilepsia. 2016 Apr;57(4):557-65. doi: 10.1111/epi.13330. Epub 2016 Mar 6.

24.

A RelA(p65) Thr505 phospho-site mutation reveals an important mechanism regulating NF-κB-dependent liver regeneration and cancer.

Moles A, Butterworth JA, Sanchez A, Hunter JE, Leslie J, Sellier H, Tiniakos D, Cockell SJ, Mann DA, Oakley F, Perkins ND.

Oncogene. 2016 Sep 1;35(35):4623-32. doi: 10.1038/onc.2015.526. Epub 2016 Feb 8.

25.

c-Rel and its many roles in cancer: an old story with new twists.

Hunter JE, Leslie J, Perkins ND.

Br J Cancer. 2016 Jan 12;114(1):1-6. doi: 10.1038/bjc.2015.410. Review.

26.

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.

Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patterson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole M, Allinson LM, Wallis JP, Marshall S, Wang E, Curtin NJ, Willmore E.

Oncotarget. 2015 Dec 22;6(41):43978-91. doi: 10.18632/oncotarget.6287.

27.

The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma.

Hunter JE, Butterworth JA, Zhao B, Sellier H, Campbell KJ, Thomas HD, Bacon CM, Cockell SJ, Gewurz BE, Perkins ND.

Oncogene. 2016 Jun 30;35(26):3476-84. doi: 10.1038/onc.2015.399. Epub 2015 Nov 2.

28.

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.

Walton MI, Eve PD, Hayes A, Henley AT, Valenti MR, De Haven Brandon AK, Box G, Boxall KJ, Tall M, Swales K, Matthews TP, McHardy T, Lainchbury M, Osborne J, Hunter JE, Perkins ND, Aherne GW, Reader JC, Raynaud FI, Eccles SA, Collins I, Garrett MD.

Oncotarget. 2016 Jan 19;7(3):2329-42. doi: 10.18632/oncotarget.4919.

29.

Universal tumor screening for Lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers.

Hunter JE, Zepp JM, Gilmore MJ, Davis JV, Esterberg EJ, Muessig KR, Peterson SK, Syngal S, Acheson LS, Wiesner GL, Reiss JA, Goddard KA.

Cancer. 2015 Sep 15;121(18):3281-9. doi: 10.1002/cncr.29470. Epub 2015 Jun 2.

30.

Evolution from the TUG to PAP flap for breast reconstruction: Comparison and refinements of technique.

Hunter JE, Lardi AM, Dower DR, Farhadi J.

J Plast Reconstr Aesthet Surg. 2015 Jul;68(7):960-5. doi: 10.1016/j.bjps.2015.03.011. Epub 2015 Mar 19.

PMID:
25913410
31.

Microvascular modifications to optimize the transverse upper gracilis flap for breast reconstruction.

Hunter JE, Mackey SP, Boca R, Harris PA.

Plast Reconstr Surg. 2014 Jun;133(6):1315-25. doi: 10.1097/PRS.0000000000000173.

PMID:
24569421
32.

Using body temperature, food and water consumption as biomarkers of disease progression in mice with Eμ-myc lymphoma.

Hunter JE, Butterworth J, Perkins ND, Bateson M, Richardson CA.

Br J Cancer. 2014 Feb 18;110(4):928-34. doi: 10.1038/bjc.2013.818. Epub 2014 Jan 9.

33.

The association of low socioeconomic status and the risk of having a child with Down syndrome: a report from the National Down Syndrome Project.

Hunter JE, Allen EG, Shin M, Bean LJ, Correa A, Druschel C, Hobbs CA, O'Leary LA, Romitti PA, Royle MH, Torfs CP, Freeman SB, Sherman SL.

Genet Med. 2013 Sep;15(9):698-705. doi: 10.1038/gim.2013.34. Epub 2013 Apr 4.

34.

Genetic load is associated with hypothalamic-pituitary-adrenal axis dysregulation in macaques.

Ferguson B, Hunter JE, Luty J, Street SL, Woodall A, Grant KA.

Genes Brain Behav. 2012 Nov;11(8):949-57. doi: 10.1111/j.1601-183X.2012.00856.x. Epub 2012 Oct 13.

35.

Depression and anxiety symptoms among women who carry the FMR1 premutation: impact of raising a child with fragile X syndrome is moderated by CRHR1 polymorphisms.

Hunter JE, Leslie M, Novak G, Hamilton D, Shubeck L, Charen K, Abramowitz A, Epstein MP, Lori A, Binder E, Cubells JF, Sherman SL.

Am J Med Genet B Neuropsychiatr Genet. 2012 Jul;159B(5):549-59. doi: 10.1002/ajmg.b.32061. Epub 2012 May 9.

36.

Capturing the fragile X premutation phenotypes: a collaborative effort across multiple cohorts.

Hunter JE, Sherman S, Grigsby J, Kogan C, Cornish K.

Neuropsychology. 2012 Mar;26(2):156-64. doi: 10.1037/a0026799. Epub 2012 Jan 16.

37.

The FMR1 premutation and attention-deficit hyperactivity disorder (ADHD): evidence for a complex inheritance.

Hunter JE, Epstein MP, Tinker SW, Abramowitz A, Sherman SL.

Behav Genet. 2012 May;42(3):415-22. doi: 10.1007/s10519-011-9520-z. Epub 2011 Nov 19.

38.

NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699.

Hunter JE, Willmore E, Irving JA, Hostomsky Z, Veuger SJ, Durkacz BW.

Oncogene. 2012 Jan 12;31(2):251-64. doi: 10.1038/onc.2011.229. Epub 2011 Jun 27.

39.

Evaluating gene expression in C57BL/6J and DBA/2J mouse striatum using RNA-Seq and microarrays.

Bottomly D, Walter NA, Hunter JE, Darakjian P, Kawane S, Buck KJ, Searles RP, Mooney M, McWeeney SK, Hitzemann R.

PLoS One. 2011 Mar 24;6(3):e17820. doi: 10.1371/journal.pone.0017820.

40.

Neuropsychological findings from older premutation carrier males and their noncarrier siblings from families with fragile X syndrome.

Allen EG, Hunter JE, Rusin M, Juncos J, Novak G, Hamilton D, Shubeck L, Charen K, Sherman SL.

Neuropsychology. 2011 May;25(3):404-411. doi: 10.1037/a0021879.

41.

Use of acupuncture in veterinary medicine.

Hunter JE.

Vet Rec. 2010 Dec 11;167(24):947-8. doi: 10.1136/vr.c7045. No abstract available.

PMID:
21262701
42.

Digital nerve tumour: duped by Dupuytren's disease.

Naderi N, Hunter JE, Boyce DE.

J Hand Surg Eur Vol. 2010 May;35(4):329-30. doi: 10.1177/1753193409341891. No abstract available.

PMID:
20444795
43.

A Variance-Component Framework for Pedigree Analysis of Continuous and Categorical Outcomes.

Epstein MP, Hunter JE, Allen EG, Sherman SL, Lin X, Boehnke M.

Stat Biosci. 2009 Nov;1(2):181-198.

44.

Co-occurring diagnoses among FMR1 premutation allele carriers.

Hunter JE, Rohr JK, Sherman SL.

Clin Genet. 2010 Apr;77(4):374-81. doi: 10.1111/j.1399-0004.2009.01317.x. Epub 2010 Jan 6.

45.

Demand management in plastic surgery for low priority procedures: the Welsh experience.

Hunter JE, Laing JH, Carroll G.

J Plast Reconstr Aesthet Surg. 2010 Nov;63(11):1778-86. doi: 10.1016/j.bjps.2009.11.008. Epub 2009 Dec 7.

PMID:
19969515
46.

Cardiovascular disease risk of dietary stearic acid compared with trans, other saturated, and unsaturated fatty acids: a systematic review.

Hunter JE, Zhang J, Kris-Etherton PM.

Am J Clin Nutr. 2010 Jan;91(1):46-63. doi: 10.3945/ajcn.2009.27661. Epub 2009 Nov 25. Review.

PMID:
19939984
47.

Protecting microvascular anastomoses from desiccation during lengthy procedures.

Hunter JE, Josty IC.

J Plast Reconstr Aesthet Surg. 2010 May;63(5):e494. doi: 10.1016/j.bjps.2009.08.016. Epub 2009 Sep 18. No abstract available.

PMID:
19766551
48.

A phase I-II trial of weekly topotecan in the treatment of recurrent cervical carcinoma.

Puls LE, Phillips B, Schammel C, Hunter JE, Griffin D.

Med Oncol. 2010 Jun;27(2):368-72. doi: 10.1007/s12032-009-9219-7. Epub 2009 Apr 21.

PMID:
19381891
49.

Is there evidence for neuropsychological and neurobehavioral phenotypes among adults without FXTAS who carry the FMR1 premutation? A review of current literature.

Hunter JE, Abramowitz A, Rusin M, Sherman SL.

Genet Med. 2009 Feb;11(2):79-89. doi: 10.1097/GIM.0b013e31818de6ee. Review.

50.

Sciatic neuroma presenting forty years after above-knee amputation.

Kitcat M, Hunter JE, Malata CM.

Open Orthop J. 2009 Dec 30;3:125-7. doi: 10.2174/1874325000903010125.

Supplemental Content

Loading ...
Support Center